Alison Birtle gives an update on the POUT trial on the use of adjuvant chemotherapy after nephroureterectomy for UTUC. Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer. Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024. Michiel Van der Heijdan explores the role of radiotherapy and other neoadjuvant combinations for MIBC. Dr. Galsky discusses his phase 2 study evaluating the effects of gem/cis/nivo followed by nivolumab in responders. The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564. Andrea Apolo, MD, discusses the phase III AMBASSADOR study that investigated adjuvant pembrolizumab against observation. Elena Castro, Begoña Valerrama and Cristina Suárez analyze some of the urothelial carcinoma research highlights of 2023. Dr. Kala Sridhar joins the podcast to discuss updates and advancements in the bladder cancer field in 2023. Matt Galsky continues his discussion on ctDNA in bladder cancer and covers topics such as candidate versus panel approaches. Dr. James Catto joins the podcast to compare robotic cystectomy against open cystectomy for patients with bladder cancer. Ananya Choudhury explains trimodality therapy for bladder cancer and myths around trimodal therapy and radical cystectomy. Matt Galsky, MD, talks about his new ctDNA study as well as how ctDNA may play a role in upcoming neoadjuvant trials. Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC. Shilpa Gupta, MD discusses two oral abstracts from ASCO 2023 on the CONTACT-03 trial and the EV-103 trial. Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC. Sia Daneshmand, MD, reviews 2 studies on the use of erdafitinib for the treatment of NMIBC, including the THOR-2 trial. The Uromigos are joined by Kala Sridhar, MD, to discuss the PET MUSE study on the impact of PET imaging in MIUC. Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium. Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos.